The cost-effectiveness of induction immunosuppression in kidney transplantation

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2258-2269

  Morton, Rachael L ^a   Howard, Kirsten ^a   Webster, Angela C ^a,b   Wong, Germaine ^b   Craig, Jonathan C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Cost effectiveness; Immunosuppression; Kidney transplant; QALYs

Indexed keywords

INTERLEUKIN 2 RECEPTOR ANTIBODY; POLYCLONAL ANTIBODY;

ARTICLE; COST EFFECTIVENESS ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; SURVIVAL; SURVIVAL TIME;

COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2;

EID: 67651112007     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp174     Document Type: Article

References (49)

1. Webster AC, Playford EG, Higgins GY et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2004; Issue 1. Art. No.: CD003897. DOI: 10.1002/14651858.CD003897.pub2
2. Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-176
3. Webster AC. The addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients. Nephrology 2007; 12: S75-S84
4. National Institute for Clinical Evaluation (NICE). Immunosuppressive therapy for renal transplantation in adults. Technology Appraisal 85, London, 2004
5. National Guideline Clearinghouse. Immunosuppressive therapy for renal transplantation in adults. National Institute for Health and Clinical Excellence (NICE) - National Government Agency [Non-U.S.]. US Dept of Human Services, 2004
6. United States Department of Health and Human Services. OPTN/SRTR Annual Report. Chapter IV Kidney and Pancreas Transplantation in the United States, 1996-2005. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients, United States Government, 2006, 1-20
7. Australia and New Zealand Dialysis and Transplant Registry (ANZ-DATA). Special data request, 2008
8. NHS Scotland. Rabbit anti-human thymocyte immunoglobulin, 25 mg powder for solution for infusion (thymoglobuline). Consortium SM, 2008; 1-7
9. Vathsala A, ATR. Immunosuppression use in renal transplantation from Asian transplant centers: a preliminary report from the Asian Transplant Registry. Transplant Proc 2004; 36: 1868-1870
10. Kälble T, Lucan M, Nicita G et al. Guidelines on renal transplantation. European Association of Urology, 2008, 43-46
11. Hirth RA. The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ 2007; 7: 301-318
12. Nicholson T, Roderick P. International Study of Health Care Organization and Financing of renal services in England and Wales. Int J Health Care Finance Econ 2007; 7: 283-299
13. Dor A, Pauly MV, Eichleay MA et al. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007; 7: 73-111
14. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford, UK: Oxford University Press, 2006
15. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. OPTN/SRTR Annual Report. US Dept of Human Services Services, Ann Arbour, MI, 2007
16. Campbell S, Mc Donald S, Chang S et al. ANZDATA Registry Report, vol. 8, 2007, 1-22
17. U.S. Renal Data System. USRDS, National Institute of Diabetes and Digestive and Kidney Diseases. 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, 2007
18. European Renal Association-European Dialysis and Transplant Association. ERA-EDTA Registry 2005 Annual Report. Academic Medical Center Department of Medical Informatics, Amsterdam, The Netherlands, 2007
19. Australian Institute of Health and Welfare. Health Expenditure Australia 2005-2006. Cat. no. HWE 37, Canberra, 2007
20. Pharmaceutical Benefits Advisory Committee, Department of Health and Ageing. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth of Australia, 2006
21. McDonald S, Chang S, Excell L. Method and location of dialysis. Adelaide: Australia and New Zealand Dialysis and Transplant Registry Report. 2007
22. Laupacis A, Keown P, Pus N. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50 235-242
23. Gorodetskaya I, Zenios S, McCulloch CE et al. Health-related quality of life and estimates of utility in chronic kidney disease Kidney Int 2005; 68: 2801-2808
24. Van Den Hout WB, Van Der Linden YM, Steenland E et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial JNatl Cancer Inst 2003; 95: 222-229
25. Australian Government, Department of Health and Ageing. Australian Refined Diagnosis Related Groups (ARDRG) - Cost Report, 2007
26. Australian Government, Department of Health and Ageing. Medicare Benefits Schedule. Canberra: Commonwealth of Australia, 2008
27. Department of Human Services. Renal Dialysis Costing and Funding Review. Melbourne, VIC: DHS, 2007.
28. Australian Government, Department of Health and Ageing. Pharmaceutical Benefits Scheme. Canberra: Commonwealth of Australia, 2007
29. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716-717
30. Pearson SD, Rawlins MD. NICE and the British National Health Service. JAMA 2005; 294: 2618-2622
31. Harris A, Hill SR, Chin G et al. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 2008; 28: 713-722
32. Peeters P, Rublee D, Just PM et al. Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy 2000; 54: 209-227
33. OECD. Main economic indicators. Purchasing power parity. 2008, 280. ISSN 0474-5523 - %A9 OECD
34. Garcia R, Hanzawa NM, Machado PGP et al. Calcineurin inhibitor-free regimen for low risk kidney transplant recipients (abstract). XIXth International Congress of the Transplantation Society, Miami, USA, 25-30 August 2002
35. Baczkowska T, Perkowska A, Cieciura T et al. Daclizumab allows for a protocol with low-dose cyclosporine in low rejection-risk kidney recipients - preliminary data (abstract). Nephrol Dial Transplant 2003; 17(Suppl 12): 309
36. Vella J, Brennan DC. Induction immunosuppressive therapy in renal transplantation. Available at: http://www.uptodate.com/home/store/index.do (cited 28 May 2008)
37. Sheashaa HA, Bakr MA, Ismail AM et al. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol 2003; 16: 393-398
38. Polsky D, Weinfurt KP, Kaplan B et al. An economic and quality of life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol Dial Transplant 2001; 16: 1028-1033
39. Woodroffe R, Yao GL, Meads C et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9
40. Yao G, Albon E, Adi Y et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess 2006; 10(49): iii-iv, ix-xi, 1-157
41. National Health and Medical Research Council (NHMRC). How to use the evidence: assessment and application of scientific evidence. Commonwealth of Australia, Canberra, 2000, 6-10
42. National Health and Medical Research Council (NHMRC). How to compare the costs and benefits: evaluation of the economic evidence. Commonwealth of Australia, Canberra, 2001, 65
43. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immuno-suppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22: 200-210
44. Thomas PG, Woodside KJ, Lappin J et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509-1512
45. Vathsala A, Ona ET, Tan S-Y et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765-774
46. Hasegawa T, Imai H, Miki S. Cost evaluation of Basiliximab treatment for renal transplant patients in Japan. Pharmacoeconomics 2003; 21: 791-806
47. Chadban S. ANZDATA Registry Report. Adelaide, SA: Australia and New Zealand Dialysis and Transplant Registry, 2002
48. Vandikar AV, Trivedi HL. Chronic rejection: an enduring enigma of transplantation biology. Transplant Proc 2007; 39: 773-778
49. Russ GR. ANZDATA Registry Report. Adelaide, SA: Australia and New Zealand Dialysis and Transplant Registry, 2000, 82